On February 10, 2012, BIO and PhRMA filed an amicus brief for the Marine Polymer Technologies Federal Circuit en banc review, addressing the issue of whether a patent owner whose patent survives reexamination without amendment may still enforce the patent against an infringer, without being limited by intervening rights.
Michael Gollin was lead counsel, working with Venable attorneys Bill Coston
, Martin Saad
, Meaghan Kent
, and Fabian Koenigbauer.